MCM
IKT icon

MAI Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

MAI Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-91
Closed -$153 – 3343
2026
Q1 		$153 Buy
+91
New +$162 ﹤0.01% 4672

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MAI Capital Management's IKT Position: Q2 2026 in Review

MAI Capital Management sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 91 shares — an estimated $153 sold.

MAI Capital Management first reported a position in IKT in Q1 2026 and held it in 1 quarter. The position peaked at $153 in Q1 2026. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • MAI Capital Management reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 91 Inhibikase Therapeutics shares in Q2 2026, an estimated $153.
  • MAI Capital Management first reported a position in Inhibikase Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Inhibikase Therapeutics position peaked at $153 in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.